Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

被引：0
|
作者：
Santoro, Armando [1 ,2 ]
Johnson, Nathalie A. [3 ]
Savage, Kerry J. [4 ]
Avigdor, Abraham [5 ]
Bazargan, Ali [6 ,7 ]
Borchmann, Peter [8 ]
Gasiorowski, Robin [9 ]
Gregory, Gareth P. [10 ]
Herishanu, Yair [11 ]
Madan, Sumit [12 ]
Minuk, Leonard [13 ,14 ]
Musuraca, Gerardo [15 ]
West, Rachel Marceau [16 ]
Pillai, Pallavi [16 ]
Marinello, Patricia [16 ]
Zinzani, Pier Luigi [17 ,18 ]
机构：
[1] Humanitas Univ, Pieve Emanuele, Milan, Italy
[2] IRCCS Humanitas Res Hosp Humanitas Canc Ctr Rozza, Milan, Italy
[3] Jewish Gen Hosp, Montreal, PQ, Canada
[4] BC Canc, Div Med Oncol, Vancouver, BC, Canada
[5] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel
[6] Univ Melbourne, Melbourne, Vic, Australia
[7] St Vincents Hosp, Fitzroy, Vic, Australia
[8] Univ Hosp Cologne, Cologne, Germany
[9] Univ Sydney, Concord Hosp, Concord, NSW, Australia
[10] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
[11] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[12] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[13] CancerCare Manitoba, Winnipeg, MB, Canada
[14] Univ Manitoba, Winnipeg, MB, Canada
[15] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, Italy
[16] Merck & Co Inc, Rahway, NJ USA
[17] Univ Bologna Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
[18] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182536
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    BLOOD, 2022, 140 : 3728 - 3730
  • [42] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Giri, Pratyush
    Patil, Sushrut
    Ratnasingam, Sumita
    Prince, H. Miles
    Milliken, Samuel
    Meijide, Javier Briones
    Coyle, Luke
    Van der Poel, Marjolein
    Mulroney, Carolyn M.
    Farooqui, Mohammed Z. H.
    Wong, Hansen
    Desai, Rajendra
    Zugmaier, Gerhard
    Mergen, Noemi
    Cannell, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma
    Hatton, C. S. R.
    Peniket, A.
    Tusold, A.
    Collins, G. P.
    Joyner, M.
    Lee, R.
    Mouncey, P.
    Smith, P.
    Lee, S-M
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 13 - 13
  • [44] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [45] Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
    Herrera, Alex F.
    Chen, Lu
    Popplewell, Leslie L.
    Budde, Lihua E.
    Mei, Matthew
    Armenian, Saro H.
    Darrah, Justin
    Nikolaenko, Liana
    Chen, Robert W.
    Peters, Lacolle
    Kennedy, Neena
    Rosen, Steven
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2019, 134
  • [46] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    Hutchings, Martin
    Mous, Rogier
    Clausen, Michael Roost
    Johnson, Peter
    Linton, Kim M.
    Chamuleau, Martine E. D.
    Lewis, David John
    Balari, Anna Sureda
    Cunningham, David
    Oliveri, Roberto S.
    Elliott, Brian
    DeMarco, Dena
    Azaryan, Ada
    Chiu, Christopher
    Li, Tommy
    Chen, Kuo-mei
    Ahmadi, Tahamtan
    Lugtenburg, Pieternella J.
    LANCET, 2021, 398 (10306): : 1157 - 1169
  • [47] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
  • [49] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [50] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
    Luscan, Gerald
    Paccagnella, Luisa
    Patel, Krish
    BLOOD, 2023, 142
12345